146 related articles for article (PubMed ID: 17694505)
21. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
Flint A; Kapitza C; Hindsberger C; Zdravkovic M
Adv Ther; 2011 Mar; 28(3):213-26. PubMed ID: 21340616
[TBL] [Abstract][Full Text] [Related]
22. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
[TBL] [Abstract][Full Text] [Related]
23. The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes.
Rodriguez LM; Mason KJ; Haymond MW; Heptulla RA
Pediatr Res; 2007 Dec; 62(6):746-9. PubMed ID: 17957149
[TBL] [Abstract][Full Text] [Related]
24. Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes.
Wysham C; Lush C; Zhang B; Maier H; Wilhelm K
Curr Med Res Opin; 2008 Jan; 24(1):79-85. PubMed ID: 18031595
[TBL] [Abstract][Full Text] [Related]
25. Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight.
Karl D; Philis-Tsimikas A; Darsow T; Lorenzi G; Kellmeyer T; Lutz K; Wang Y; Frias JP
Diabetes Technol Ther; 2007 Apr; 9(2):191-9. PubMed ID: 17425446
[TBL] [Abstract][Full Text] [Related]
26. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.
Kolterman OG; Schwartz S; Corder C; Levy B; Klaff L; Peterson J; Gottlieb A
Diabetologia; 1996 Apr; 39(4):492-9. PubMed ID: 8778001
[TBL] [Abstract][Full Text] [Related]
27. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
[TBL] [Abstract][Full Text] [Related]
28. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size.
Jovanovic L; Giammattei J; Acquistapace M; Bornstein K; Sommermann E; Pettitt DJ
Clin Ther; 2004 Sep; 26(9):1492-7. PubMed ID: 15531011
[TBL] [Abstract][Full Text] [Related]
29. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus.
Nyholm B; Orskov L; Hove KY; Gravholt CH; Møller N; Alberti KG; Moyses C; Kolterman O; Schmitz O
Metabolism; 1999 Jul; 48(7):935-41. PubMed ID: 10421239
[TBL] [Abstract][Full Text] [Related]
30. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes.
Linnebjerg H; Park S; Kothare PA; Trautmann ME; Mace K; Fineman M; Wilding I; Nauck M; Horowitz M
Regul Pept; 2008 Nov; 151(1-3):123-9. PubMed ID: 18675854
[TBL] [Abstract][Full Text] [Related]
31. The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes.
Amiel SA; Heller SR; Macdonald IA; Schwartz SL; Klaff LJ; Ruggles JA; Weyer C; Kolterman OG; Maggs DG
Diabetes Obes Metab; 2005 Sep; 7(5):504-16. PubMed ID: 16050943
[TBL] [Abstract][Full Text] [Related]
32. Nitrotyrosine: new findings as a marker of postprandial oxidative stress.
Ceriello A
Int J Clin Pract Suppl; 2002 Jul; (129):51-8. PubMed ID: 12166608
[TBL] [Abstract][Full Text] [Related]
33. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes.
Ratner RE; Want LL; Fineman MS; Velte MJ; Ruggles JA; Gottlieb A; Weyer C; Kolterman OG
Diabetes Technol Ther; 2002; 4(1):51-61. PubMed ID: 12017421
[TBL] [Abstract][Full Text] [Related]
34. Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients.
Assaloni R; Da Ros R; Quagliaro L; Piconi L; Maier A; Zuodar G; Motz E; Ceriello A
Diabetologia; 2005 Sep; 48(9):1919-24. PubMed ID: 16007412
[TBL] [Abstract][Full Text] [Related]
35. Postprandial total and HMW adiponectin following a high-fat meal in lean, obese and diabetic men.
Phillips LK; Peake JM; Zhang X; Hickman IJ; Briskey DR; Huang BE; Simpson P; Li SH; Whitehead JP; Martin JH; Prins JB
Eur J Clin Nutr; 2013 Apr; 67(4):377-84. PubMed ID: 23462948
[TBL] [Abstract][Full Text] [Related]
36. Optimal dose and timing of insulin Aspart to mimic first phase insulin response in patients with recently onset type 2 diabetes.
Gredal C; Rosenfalck A; Dejgaard A; Hilsted J
Diabetes Res Clin Pract; 2008 May; 80(2):293-8. PubMed ID: 18304675
[TBL] [Abstract][Full Text] [Related]
37. Effect of Pramlintide on Postprandial Glucose Fluxes in Type 1 Diabetes.
Hinshaw L; Schiavon M; Dadlani V; Mallad A; Dalla Man C; Bharucha A; Basu R; Geske JR; Carter RE; Cobelli C; Basu A; Kudva YC
J Clin Endocrinol Metab; 2016 May; 101(5):1954-62. PubMed ID: 26930181
[TBL] [Abstract][Full Text] [Related]
38. Humalog Mix25 offers better mealtime glycemic control in patients with type 1 or type 2 diabetes.
Malone JK; Yang H; Woodworth JR; Huang J; Campaigne BN; Halle JP; Yale JF; Grossman LD
Diabetes Metab; 2000 Dec; 26(6):481-7. PubMed ID: 11173719
[TBL] [Abstract][Full Text] [Related]
39. Dietary treatment with rice containing resistant starch improves markers of endothelial function with reduction of postprandial blood glucose and oxidative stress in patients with prediabetes or newly diagnosed type 2 diabetes.
Kwak JH; Paik JK; Kim HI; Kim OY; Shin DY; Kim HJ; Lee JH; Lee JH
Atherosclerosis; 2012 Oct; 224(2):457-64. PubMed ID: 22954674
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of an oral drug (acetaminophen) administered at various times relative to subcutaneous injection of pramlintide in subjects with type 2 diabetes.
Kellmeyer TA; Kesty NC; Wang Y; Frias JP; Fineman MS
J Clin Pharmacol; 2007 Jul; 47(7):798-805. PubMed ID: 17463219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
